CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, P.
Right arrow Articles by Peters, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, P.
Right arrow Articles by Peters, K. G.

Cell Growth & Differentiation, Vol 9, Issue 1 49-58, Copyright © 1998 by American Association of Cancer Research


ARTICLES

Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor

P Lin, S Sankar, S Shan, MW Dewhirst, PJ Polverini, TQ Quinn and KG Peters
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

Vascular endothelial growth factor (VEGF) is a leading candidate for an endogenous mediator of tumor angiogenesis. Recently, two endothelial cell surface receptors, flk-1 and flt-1, have been shown to mediate the angiogenic activities of VEGF. In this study, we have evaluated whether a soluble VEGF receptor could suppress tumor angiogenesis and thereby inhibit tumor growth. A soluble VEGF receptor was constructed by fusing the entire extracellular domain of murine flk-1 to a six-histidine tag at the COOH terminus (ExFlk.6His). In vitro, recombinant ExFlk.6His protein bound VEGF with high affinity (Kd, 16 nM) and blocked receptor activation in a dose-dependent manner and inhibited VEGF-induced endothelial cell proliferation and migration. ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. In vivo, ExFlk.6His potently inhibited corneal neovascularization induced by conditioned media from a rat mammary carcinoma cell line (R3230AC). Moreover, when ExFlk.6His protein was administered into a cutaneous tumor window chamber concomitantly with R3230AC carcinoma transplants, tumor growth was inhibited by 75% (P < 0.005) and vascular density was reduced by 50% (P < 0.002) compared with control-treated tumors. These results demonstrate the potential of ExFlk.6His to inhibit VEGF action by a potent "dominant-negative" mechanism and suggest that targeting VEGF action using a soluble receptor may be an effective antiangiogenic therapy for cancer and other "angiogenic" diseases.


This article has been cited by other articles:


Home page
IOVSHome page
D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K.-H. Thierauch, and C. Cursiefen
Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation
, May 1, 2008; 49(5): 1836 - 1842.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Sini, I. Samarzija, F. Baffert, A. Littlewood-Evans, C. Schnell, A. Theuer, S. Christian, A. Boos, H. Hess-Stumpp, J. A. Foekens, et al.
Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
Cancer Res., March 1, 2008; 68(5): 1581 - 1592.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
E. Geretti, A. Shimizu, P. Kurschat, and M. Klagsbrun
Site-directed Mutagenesis in the B-Neuropilin-2 Domain Selectively Enhances Its Affinity to VEGF165, but Not to Semaphorin 3F
J. Biol. Chem., August 31, 2007; 282(35): 25698 - 25707.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan
Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells
Cancer Res., April 15, 2007; 67(8): 3683 - 3690.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Cao, P. Sonveaux, S. Liu, Y. Zhao, J. Mi, B. M. Clary, C.-Y. Li, C. D. Kontos, and M. W. Dewhirst
Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth
Cancer Res., April 15, 2007; 67(8): 3835 - 3844.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. Menendez, A. Inga, J. Snipe, O. Krysiak, G. Schonfelder, and M. A. Resnick
A Single-Nucleotide Polymorphism in a Half-Binding Site Creates p53 and Estrogen Receptor Control of Vascular Endothelial Growth Factor Receptor 1
Mol. Cell. Biol., April 1, 2007; 27(7): 2590 - 2600.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Li, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao
Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-{kappa}B Transcriptional Activity
Clin. Cancer Res., April 1, 2007; 13(7): 2178 - 2190.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. Singh, P. D. Jani, T. Suthar, S. Amin, and B. K. Ambati
Flt-1 Intraceptor Induces the Unfolded Protein Response, Apoptotic Factors, and Regression of Murine Injury-Induced Corneal Neovascularization
, November 1, 2006; 47(11): 4787 - 4793.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Luo, Y.-J. Wen, Z.-Y. Ding, C.-H. Fu, Y. Wu, J.-Y. Liu, Q. Li, Q.-M. He, X. Zhao, Y. Jiang, et al.
Immunotherapy of tumors with protein vaccine based on chicken homologous tie-2.
Clin. Cancer Res., March 15, 2006; 12(6): 1813 - 1819.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. Zent and A. Pozzi
Antiangiogenic Therapy in Diabetic Nephropathy
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 325 - 327.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. Singh, S. Amin, E. Richter, S. Rashid, V. Scoglietti, P. D. Jani, J. Wang, R. Kaur, J. Ambati, Z. Dong, et al.
Flt-1 Intraceptors Inhibit Hypoxia-Induced VEGF Expression In Vitro and Corneal Neovascularization In Vivo
, May 1, 2005; 46(5): 1647 - 1652.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Schmidt, J. Hoffend, A. Altmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, B. Engelhardt, D. Koczan, J. Peter, S. Vorwald, H. Eskerski, et al.
Transfer of the sFLT-1 Gene in Morris Hepatoma Results in Decreased Growth and Perfusion and Induction of Genes Associated with Stress Response
Clin. Cancer Res., March 15, 2005; 11(6): 2132 - 2140.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge
ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity
Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Z. Olenyuk, G.-J. Zhang, J. M. Klco, N. G. Nickols, W. G. Kaelin Jr., and P. B. Dervan
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
PNAS, November 30, 2004; 101(48): 16768 - 16773.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Shiojima and K. Walsh
The Role of Vascular Endothelial Growth Factor in Restenosis: The Controversy Continues
Circulation, October 19, 2004; 110(16): 2283 - 2286.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. L. Rakhmilevich, A. T. Hooper, D. J. Hicklin, and P. M. Sondel
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody
Mol. Cancer Ther., August 1, 2004; 3(8): 969 - 976.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. M.L. Ebos, G. Bocci, S. Man, P. E. Thorpe, D. J. Hicklin, D. Zhou, X. Jia, and R. S. Kerbel
A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma
Mol. Cancer Res., June 1, 2004; 2(6): 315 - 326.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
N. H. Fernando and H. I. Hurwitz
Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab
Oncologist, June 1, 2004; 9(suppl_1): 11 - 18.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Shao, S. Bao, X. Bai, C. Blanchette, R. M. Anderson, T. Dang, M. L. Gishizky, J. R. Marks, and X.-F. Wang
Acquired Expression of Periostin by Human Breast Cancers Promotes Tumor Angiogenesis through Up-Regulation of Vascular Endothelial Growth Factor Receptor 2 Expression
Mol. Cell. Biol., May 1, 2004; 24(9): 3992 - 4003.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. J. Mahasreshti, M. Kataram, M. H. Wang, C. R. Stockard, W. E. Grizzle, D. Carey, G. P. Siegal, H. J. Haisma, R. D. Alvarez, and D. T. Curiel
Intravenous Delivery of Adenovirus-mediated Soluble FLT-1 Results in Liver Toxicity
Clin. Cancer Res., July 1, 2003; 9(7): 2701 - 2710.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
N. Cheng, D. M. Brantley, H. Liu, Q. Lin, M. Enriquez, N. Gale, G. Yancopoulos, D. P. Cerretti, T. O. Daniel, and J. Chen
Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis
Mol. Cancer Res., November 1, 2002; 1(1): 2 - 11.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. W. Spurbeck, C. Y. C. Ng, T. S. Strom, E. F. Vanin, and A. M. Davidoff
Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model
Blood, October 16, 2002; 100(9): 3361 - 3368.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Stopeck, M. Sheldon, M. Vahedian, G. Cropp, R. Gosalia, and A. Hannah
Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies
Clin. Cancer Res., September 1, 2002; 8(9): 2798 - 2805.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Edwards, L. Geng, J. Tan, H. Onishko, E. Donnelly, and D. E. Hallahan
Phosphatidylinositol 3-Kinase/Akt Signaling in the Response of Vascular Endothelium to Ionizing Radiation
Cancer Res., August 15, 2002; 62(16): 4671 - 4677.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. M. Davidoff, A. C. Nathwani, W. W. Spurbeck, C. Y. C. Ng, J. Zhou, and E. F. Vanin
rAAV-mediated Long-term Liver-generated Expression of an Angiogenesis Inhibitor Can Restrict Renal Tumor Growth in Mice
Cancer Res., June 1, 2002; 62(11): 3077 - 3083.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. M. Davidoff, C. Y. C. Ng, P. Brown, M. A. Leary, W. W. Spurbeck, J. Zhou, E. Horwitz, E. F. Vanin, and A. W. Nienhuis
Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice
Clin. Cancer Res., September 1, 2001; 7(9): 2870 - 2879.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Shan, A. C. Lockhart, W. Y. Saito, A. M. Knapp, K. R. Laderoute, and M. W. Dewhirst
The Novel Tubulin-binding Drug BTO-956 Inhibits R3230Ac Mammary Carcinoma Growth and Angiogenesis in Fischer 344 Rats
Clin. Cancer Res., August 1, 2001; 7(8): 2590 - 2596.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. L. Harris, P. Reusch, B. Barleon, C. Hang, N. Dobbs, and D. Marme
Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy
Clin. Cancer Res., July 1, 2001; 7(7): 1992 - 1997.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. J. Mahasreshti, J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, et al.
Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma
Clin. Cancer Res., July 1, 2001; 7(7): 2057 - 2066.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q. Shi, X. Le, J. L. Abbruzzese, Z. Peng, C.-N. Qian, H. Tang, Q. Xiong, B. Wang, X.-C. Li, and K. Xie
Constitutive Sp1 Activity Is Essential for Differential Constitutive Expression of Vascular Endothelial Growth Factor in Human Pancreatic Adenocarcinoma
Cancer Res., May 1, 2001; 61(10): 4143 - 4154.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, April 10, 2001; 98(8): 4605 - 4610.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, G. Trinchieri, C. M. Sehgal, M. D. Feldman, and W. M. F. Lee
Doppler Ultrasound Imaging Detects Changes in Tumor Perfusion during Antivascular Therapy Associated with Vascular Anatomic Alterations
Cancer Res., April 1, 2001; 61(7): 2974 - 2982.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
M. J. Currie, S. P. Gunningham, C. Han, P. A. E. Scott, B. A. Robinson, A. L. Harris, and S. B. Fox
Angiopoietin-1 Is Inversely Related to Thymidine Phosphorylase Expression in Human Breast Cancer, Indicating a Role in Vascular Remodeling
Clin. Cancer Res., April 1, 2001; 7(4): 918 - 927.
[Abstract] [Full Text]


Home page
EMBO J.Home page
T. Veikkola, L. Jussila, T. Makinen, T. Karpanen, M. Jeltsch, T. V. Petrova, H. Kubo, G. Thurston, D. M. McDonald, M. G. Achen, et al.
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
EMBO J., March 15, 2001; 20(6): 1223 - 1231.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Geng, E. Donnelly, G. McMahon, P. C. Lin, E. Sierra-Rivera, H. Oshinka, and D. E. Hallahan
Inhibition of Vascular Endothelial Growth Factor Receptor Signaling Leads to Reversal of Tumor Resistance to Radiotherapy
Cancer Res., March 1, 2001; 61(6): 2413 - 2419.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
A. Compagni, P. Wilgenbus, M.-A. Impagnatiello, M. Cotten, and G. Christofori
Fibroblast Growth Factors Are Required for Efficient Tumor Angiogenesis
Cancer Res., December 1, 2000; 60(24): 7163 - 7169.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
S. Yano, H. Shinohara, R. S. Herbst, H. Kuniyasu, C. D. Bucana, L. M. Ellis, D. W. Davis, D. J. McConkey, and I. J. Fidler
Expression of Vascular Endothelial Growth Factor Is Necessary but not Sufficient for Production and Growth of Brain Metastasis
Cancer Res., September 1, 2000; 60(17): 4959 - 4967.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
K. Takayama, H. Ueno, Y. Nakanishi, T. Sakamoto, K. Inoue, K. Shimizu, H. Oohashi, and N. Hara
Suppression of Tumor Angiogenesis and Growth by Gene Transfer of a Soluble Form of Vascular Endothelial Growth Factor Receptor into a Remote Organ
Cancer Res., April 1, 2000; 60(8): 2169 - 2177.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
J. M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O'Reilly, et al.
PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration
Cancer Res., April 1, 2000; 60(8): 2178 - 2189.
[Abstract] [Full Text]


Home page
The OncologistHome page
G. McMahon
VEGF Receptor Signaling in Tumor Angiogenesis
Oncologist, April 1, 2000; 5(90001): 3 - 10.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. L. Gagnon, D. R. Bielenberg, Z.'e. Gechtman, H.-Q. Miao, S. Takashima, S. Soker, and M. Klagsbrun
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
PNAS, March 14, 2000; 97(6): 2573 - 2578.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Yano, R. S. Herbst, H. Shinohara, B. Knighton, C. D. Bucana, J. J. Killion, J. Wood, and I. J. Fidler
Treatment for Malignant Pleural Effusion of Human Lung Adenocarcinoma by Inhibition of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Phosphorylation
Clin. Cancer Res., March 1, 2000; 6(3): 957 - 965.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, J. O. Curwen, L. F. Hennequin, A. P. Thomas, E. S. E. Stokes, B. Curry, G. H. P. Richmond, et al.
ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy
Cancer Res., February 1, 2000; 60(4): 970 - 975.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
T. Veikkola, M. Karkkainen, L. Claesson-Welsh, and K. Alitalo
Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors
Cancer Res., January 1, 2000; 60(2): 203 - 212.
[Full Text]


Home page
Cancer Res.Home page
M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, et al.
Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors
Cancer Res., October 1, 1999; 59(20): 5209 - 5218.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak
Vascular endothelial growth factor (VEGF) and its receptors
FASEB J, January 1, 1999; 13(1): 9 - 22.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. L. Gagnon, D. R. Bielenberg, Z.'e. Gechtman, H.-Q. Miao, S. Takashima, S. Soker, and M. Klagsbrun
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
PNAS, March 14, 2000; 97(6): 2573 - 2578.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, April 10, 2001; 98(8): 4605 - 4610.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.